
Alzheimer’s drug signals potential for Cambridge Cognition’s assessment solution
Following a consultation with the U.S. Food and Drug Administration, Biogen (Nasdaq:BIIB) and Eisai, Co., Ltd (Tokyo, Japan) have announced plans to pursue regulatory approval for aducanumab, which would be